EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial

Jia-Xin Wang, Yan-Li Xu, Cheng-Jie Ma, Guo-Dong Li, Yu-Xuan Yang, Jie Lian, Bo Li, Yi-Ying Wang, Jian-Ping Liu, Le Ngoc Hung, Ngo Thi Phuong, Le Minh Ha und 2 weitere

Complementary Medicine Research · 15.06.2026 · 1-9

DOI: 10.1159/000553019 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Complementary Medicine Research, online erschienen am 15.06.2026. Verfasst von Jia-Xin Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Drug Combinations, Drugs, Chinese Herbal, Fatigue, Post-Acute COVID-19 Syndrome. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Fatigue is one of the most common symptoms of post-COVID syndrome. The Chinese herbal medicine Shengmai liquid has been recorded in ancient books, and modern studies have shown its ability to relieve fatigue. This study aims to assess the clinical efficacy and safety of Shengmai liquid in improving fatigue symptoms in post-COVID syndrome patients.

Methods

We plan to enroll 100 eligible patients with post-COVID-19 fatigue from Beijing Ditan Hospital, randomly allocating them into either the Shengmai liquid or placebo group. Blinding will be maintained for the personnel responsible for evaluating outcomes and performing statistical analysis. The participants will be treated for 8 weeks and followed for another 30 days. We utilized the modified Fatigue Impact Scale as our main endpoint to evaluate changes in patient fatigue. The secondary outcomes will include the Traditional Chinese Medicine Syndrome Score Scale, Hamilton Depression Inventory-17 items, Hamilton Anxiety Scale, Pittsburgh Sleep Quality Scale, World Health Organization Quality-of-Life Scale, and 6-min walk distance. All the statistical analyses will use SPSS software with a 0.05 significance level and follow the intention-to-treat principle.

Conclusion

This randomized, single-center, double-blind trial will provide robust clinical evidence regarding the short-term efficacy and safety of Shengmai liquid for the treatment of post-COVID-19 fatigue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CombinationsDrugs, Chinese HerbalFatiguePost-Acute COVID-19 SyndromeAdultFemaleHumansMaleMiddle AgedCOVID-19COVID-19 Drug TreatmentDouble-Blind MethodQuality of LifeRandomized Controlled Trials as TopicSARS-CoV-2

Stichwörter der Autor:innen

Essai contrôlé randomiséFatiguePlaceboPost-COVID syndromePost-COVID-SyndromRandomisierte kontrollierte StudieRandomized controlled trialShengmai liquidShengmai-LiquidSolution de ShengmaiSyndrome post‑COVID

Substanzen

Drug CombinationsDrugs, Chinese Herbalfructus schizandrae, radix ginseng, radix ophiopogonis drug combination

Autor:innen und Institutionen

  • Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Beijing Ditan Hospital affiliated with Capital Medical University, Beijing, China.
  • VIPTAM Institute of Technology Application, Vietnam Union of Science and Technology Associations, Hanoi, Vietnam.
  • Institute of Chemistry, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
  • Traditional Medicine Institute, Ho Chi Minh City, Vietnam.
  • Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, huijuancao327@hotmail.com.

Zitieren

APA

Wang, J. X., Xu, Y. L., Ma, C. J., Li, G. D., Yang, Y. X., Lian, J., Li, B., Wang, Y. Y., Liu, J. P., Hung, L. N., Phuong, N. T., Ha, L. M., Lan Huong, D. T., & Cao, H. J. (2026). Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. Complementary Medicine Research, 1-9. https://doi.org/10.1159/000553019

Vancouver

Wang JX, Xu YL, Ma CJ, Li GD, Yang YX, Lian J, et al. Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. Complementary Medicine Research. 2026:1-9. doi:10.1159/000553019

BibTeX
@article{Wang2026,
  author = {Wang, Jia-Xin and Xu, Yan-Li and Ma, Cheng-Jie and Li, Guo-Dong and Yang, Yu-Xuan and Lian, Jie and Li, Bo and Wang, Yi-Ying and Liu, Jian-Ping and Hung, Le Ngoc and Phuong, Ngo Thi and Ha, Le Minh and Lan Huong, Dinh Thi and Cao, Hui-Juan},
  title = {Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Complementary Medicine Research},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000553019}
}
Kostenlos starten →